OBJECTIVES: The principal objective of our study was to document the short-term impact of the legalization of recreational cannabis on active cannabis use, cannabis use disorder, and various psychotic disorders. METHODS: We carried out a retrospective observational study of patients who were at least 12 years old and who had visited a psychiatrist in the emergency unit of the Centre hospitalier universitaire de Sherbrooke (CHUS). We included all the consultations of this type over a 5-month period, immediately following the legalization of recreational cannabis in Canada. We then divided our population into an adult (over 18) and teenager group (12 to 17) compared the data to the data from consultations made 2 years earlier, using a generalized linear mixed model. RESULTS: We examined consultations in patients over 18 years old in prelegalization (n = 1,247) and postlegalization (n = 1,368) groups. We observed a statistically significant increase in the use of cannabis (28.0% to 37.1%; odds ratio [OR] = 1.81 [1.34 to 2.44], P = 0.00011) as well as an increase in diagnoses of active cannabis use disorder (17.7% to 24.3%; OR = 1.53 [1.13 to 2.08], P = 0.0064). The increase in cannabis use disorder was more prominent among patients between 18 and 24 years old (17.3% to 25.9%; OR = 2.27 [1.17 to 4.40], P = 0.015). We observed no statistically significant difference in terms of psychotic disorder diagnoses (27.4% to 29.2%; OR = 1.17 [0.84 to 1.63], P = 0.35)]. Conversely, we identified a greater proportion of patients who had a personality disorder diagnosis in the postlegalization period (39.6% to 44.9%; OR = 1.35 [1.02 to 1.80], P = 0.038). Examination of pediatric (under 18 years old) consultations revealed no statistically significant differences. CONCLUSION: Although an affirmative conclusion is tentative, the current findings suggest a first link between the legalization of cannabis in Canada and increased diagnoses of cannabis use disorder, as well as cannabis use in general among patients in a university hospital psychiatric emergency department.
OBJECTIVES: The principal objective of our study was to document the short-term impact of the legalization of recreational cannabis on active cannabis use, cannabis use disorder, and various psychotic disorders. METHODS: We carried out a retrospective observational study of patients who were at least 12 years old and who had visited a psychiatrist in the emergency unit of the Centre hospitalier universitaire de Sherbrooke (CHUS). We included all the consultations of this type over a 5-month period, immediately following the legalization of recreational cannabis in Canada. We then divided our population into an adult (over 18) and teenager group (12 to 17) compared the data to the data from consultations made 2 years earlier, using a generalized linear mixed model. RESULTS: We examined consultations in patients over 18 years old in prelegalization (n = 1,247) and postlegalization (n = 1,368) groups. We observed a statistically significant increase in the use of cannabis (28.0% to 37.1%; odds ratio [OR] = 1.81 [1.34 to 2.44], P = 0.00011) as well as an increase in diagnoses of active cannabis use disorder (17.7% to 24.3%; OR = 1.53 [1.13 to 2.08], P = 0.0064). The increase in cannabis use disorder was more prominent among patients between 18 and 24 years old (17.3% to 25.9%; OR = 2.27 [1.17 to 4.40], P = 0.015). We observed no statistically significant difference in terms of psychotic disorder diagnoses (27.4% to 29.2%; OR = 1.17 [0.84 to 1.63], P = 0.35)]. Conversely, we identified a greater proportion of patients who had a personality disorder diagnosis in the postlegalization period (39.6% to 44.9%; OR = 1.35 [1.02 to 1.80], P = 0.038). Examination of pediatric (under 18 years old) consultations revealed no statistically significant differences. CONCLUSION: Although an affirmative conclusion is tentative, the current findings suggest a first link between the legalization of cannabis in Canada and increased diagnoses of cannabis use disorder, as well as cannabis use in general among patients in a university hospital psychiatric emergency department.
Authors: Nathan A Gillespie; Steven H Aggen; Michael C Neale; Gun Peggy Knudsen; Robert F Krueger; Susan C South; Nikolai Czajkowski; Ragnar Nesvåg; Eivind Ystrom; Kenneth S Kendler; Ted Reichborn-Kjennerud Journal: Addiction Date: 2018-04-13 Impact factor: 6.526
Authors: Wilson M Compton; Beth Han; Christopher M Jones; Carlos Blanco; Arthur Hughes Journal: Lancet Psychiatry Date: 2016-08-31 Impact factor: 27.083
Authors: Marta Di Forti; Diego Quattrone; Tom P Freeman; Giada Tripoli; Charlotte Gayer-Anderson; Harriet Quigley; Victoria Rodriguez; Hannah E Jongsma; Laura Ferraro; Caterina La Cascia; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Andrei Szöke; Celso Arango; Andrea Tortelli; Eva Velthorst; Miguel Bernardo; Cristina Marta Del-Ben; Paulo Rossi Menezes; Jean-Paul Selten; Peter B Jones; James B Kirkbride; Bart Pf Rutten; Lieuwe de Haan; Pak C Sham; Jim van Os; Cathryn M Lewis; Michael Lynskey; Craig Morgan; Robin M Murray Journal: Lancet Psychiatry Date: 2019-03-19 Impact factor: 77.056
Authors: Nora D Volkow; James M Swanson; A Eden Evins; Lynn E DeLisi; Madeline H Meier; Raul Gonzalez; Michael A P Bloomfield; H Valerie Curran; Ruben Baler Journal: JAMA Psychiatry Date: 2016-03 Impact factor: 21.596
Authors: Russell C Callaghan; Marcos Sanches; Robin M Murray; Sarah Konefal; Bridget Maloney-Hall; Stephen J Kish Journal: Can J Psychiatry Date: 2022-01-12 Impact factor: 5.321
Authors: Dafna Sara Rubin-Kahana; Jean-François Crépault; Justin Matheson; Bernard Le Foll Journal: Front Psychiatry Date: 2022-09-23 Impact factor: 5.435